Efficacy and safety of low-dose rituximab as induction therapy for antineutrophil cytoplasmic antibody-associated vasculitis with renal involvement: a Chinese case series
Abstract Background Rituximab (RTX) is a standard therapy for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). However, the most frequently used dose may lead to severe adverse effects (SAEs). We explored the efficacy and safety of low-dose RTX in Chinese patients with AAV. Me...
Main Authors: | Lin Liu, Haitao Lu, Guming Zou, Haifeng Wang, Jing Li, Yue Yang, Jian Zhang, Xueling Wang, Wenge Li, Li Zhuo |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-02-01
|
Series: | BMC Nephrology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12882-023-03075-8 |
Similar Items
-
Severe Infections following Rituximab Treatment in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis
by: Zhi-Ying Li, et al.
Published: (2020-08-01) -
ANCA Associated Vasculitis Treated with Ultra-low Dose Rituximab: A Case Report
by: WU Haiting, et al.
Published: (2023-11-01) -
Propylthiouracil-Induced Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis with Renal and Lung Involvement
by: Albert Hing Wong, et al.
Published: (2022-06-01) -
Pulmonary involvement in Anti‐Neutrophil Cytoplasmic Antibody Associated Vasculitis: A single centre case series
by: Peter T. Bell, et al.
Published: (2022-11-01) -
Clinical features and outcomes of elderly patients with antineutrophil cytoplasmic antibody-positive vasculitis: a single-center retrospective study
by: Hyo Jin Kim, et al.
Published: (2022-03-01)